Premium
Epstein‐barr virus‐associated antibodies and serum biochemistry in nasopharyngeal carcinoma
Author(s) -
Lynn TsongChou,
Hsieh RhongPhong,
Chuang CheYen,
Huang ShuChen,
Lsieh Ti,
Tu ShihMien
Publication year - 1984
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1288/00005537-198411000-00019
Subject(s) - nasopharyngeal carcinoma , mucoprotein , serology , antibody , medicine , antigen , titer , virus , capsid , metastasis , alkaline phosphatase , epstein–barr virus , immunology , virology , biology , cancer , radiation therapy , enzyme , biochemistry
Nasopharyngeal carcinoma is difficult to diagnose in its early stages. It also has frequent recurrences and/or distant metnstases after radiotherapy. Extensive clinical, serological and biochemical studies were done during 1980‐1982 on 351 patients to aid in the diagnosis of the disease, especially with recurrence or metastasis. Seropositive rates of the antibody titers against viral capsid antigens (VCA) and early antigens (EA) of Epstein‐Barr virus (EBV) in IgG and IgA classes were 41.7%‐100%. They ranked, in order of frequency: anti‐VCA/IgA, anti‐VCA/IgG, anti‐EA/IgG, and anti‐EA/IgA. Mean total serum IgG and IgA levels were moderately increased in all patients. Serum GOT, GPT, alkaline phosphatase, laclnte dehydrogenase and mucoprotein were elevated either alone or in combination in a few patients before treatment, in many patients with recurrence or metastases, and in all patients with liver metastasis.